Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, April 21, 2017
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
[ Fri, Apr 21st 2017
] - WOPRAI
Laura Chico Initiated (CDTX) at Strong Buy and Held Target at $280 on, Apr 21st, 2017
Laura Chico of Raymond James, Initiated "Cidara Therapeutics, Inc." (CDTX) at Strong Buy and Held Target at $280 on, Apr 21st, 2017.
Laura has made no other calls on CDTX in the last 4 months.
There are 4 other peers that have a rating on CDTX. Out of the 4 peers that are also analyzing CDTX, 1 agrees with Laura's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Stephen Brozak of "WBB Securities" Upgraded from Strong Sell to Hold on, Wednesday, February 22nd, 2017
These are the ratings of the 3 analyists that currently disagree with Laura
- Ed Arce of "HC Wainwright & Co." Reiterated at Strong Buy with Decreased Target to $280 on, Monday, April 17th, 2017
- Kevin DeGeeter of "Ladenburg Thalmann" Initiated at Strong Buy and Held Target at $225 on, Wednesday, April 12th, 2017
- Paul Matteis of "Leerink Swann" Initiated at Buy and Held Target at $340 on, Wednesday, December 21st, 2016
